Business Context and Reporting Period
Company: Immunome, Inc. (IMNM)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Immunome is a biotechnology company developing targeted oncology therapies, focusing on antibody-drug conjugates (ADCs) and small molecules. The company has no approved products and has not generated revenue from product sales. Its primary asset is varegacestat, a gamma secretase inhibitor for desmoid tumors, which recently completed a pivotal Phase 3 trial. The pipeline includes three clinical assets (varegacestat, IM-1021, IM-3050) and three preclinical ADCs.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $6.9 million | $9.0 million |
| Total Operating Expenses | $231.1 million | $314.8 million |
| Net Loss | $(212.4) million | $(293.0) million |
| Cash and Cash Equivalents (Year End) | $653.5 million | $143.4 million |
| Accumulated Deficit | $(728.2) million | $(515.8) million |
| Net Cash Used in Operating Activities | $(190.9) million | $(110.8) million |
| Net Cash Provided by Financing Activities | $640.4 million | $240.5 million |
Note: The company does not report gross margins or operating margins as it has no product revenue. Liquidity is strong following significant equity raises in 2025.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $2.1 million (23%) due to the termination of the AbbVie Collaboration Agreement in July 2025, with all remaining revenue recognized by Q2 2025.
- Expense Reduction: Total operating expenses decreased by $83.8 million (27%). This was primarily driven by a $142.3 million decrease in In-Process Research and Development (IPR&D) expenses. In 2024, the company expensed $152.3 million related to the write-off of acquired assets (Ayala, Zentalis, BMS). In 2025, IPR&D was only $10.0 million, representing a milestone payment for varegacestat.
- R&D Spend Increase: Direct and indirect Research and Development expenses increased by $47.7 million to $177.3 million, reflecting continued investment in the varegacestat Phase 3 trial and preparation for NDA submission.
- Liquidity Surge: Cash and cash equivalents increased by $510.2 million, driven by $633.0 million in gross proceeds from two public equity offerings (January and December 2025) and ATM sales.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Varegacestat: In December 2025, the company announced positive topline results from the Phase 3 RINGSIDE trial for desmoid tumors, meeting all primary and key secondary endpoints (84% reduction in risk of progression). An NDA submission is anticipated in Q2 2026.
- Pipeline Progress: IM-1021 (ROR1 ADC) is in Phase 1 with observed responses in B-cell lymphoma. IM-3050 (FAP Radioligand Therapy) received IND clearance in April 2025; Phase 1 initiation is planned for early 2026 pending radiotracer supply. Three preclinical ADCs (IM-1617, IM-1340, IM-1335) are expected to have IND submissions in 2026.
- Capital Runway: Management expects existing cash ($653.5 million) to fund operations for at least 12 months from the filing date (March 2026).
Risks and Contingencies
- Profitability: The company has a history of losses and expects to continue incurring significant losses for the foreseeable future. It has never achieved profitability.
- Regulatory Approval: Despite positive Phase 3 data, there is no guarantee the FDA will approve varegacestat. Approval is required to generate product revenue.
- Supply Chain: The Phase 1 trial for IM-3050 is delayed due to a sole-source vendor delay in delivering diagnostic radiotracer supply.
- Competition: Significant competition exists in desmoid tumors (e.g., Merck's OGSIVEO) and ADC/ROR1 targets (e.g., Merck, CStone).
- Financing: Future capital requirements are substantial. Additional equity financing may be required, which could result in dilution.
Investor Verification Checklist
- NDA Submission Timeline: Verify the Q2 2026 NDA submission date for varegacestat and any potential delays.
- IM-3050 Supply Chain: Confirm the resolution of the diagnostic radiotracer supply delay and the actual start date of the Phase 1 trial.
- Cash Burn Rate: Monitor quarterly cash usage to validate the 12-month runway estimate, especially as commercialization preparations for varegacestat begin.
- Milestone Obligations: Review the $10.0 million accrued milestone to Ayala and potential future milestone payments to BMS and Zentalis upon regulatory/commercial success.
- Equity Dilution: Track future equity issuances under the ATM agreement or new public offerings required to fund the commercial launch.